Free Trial

Opus Genetics (IRD) SEC Filings & 10K Form

Opus Genetics logo
$1.09 -0.02 (-1.80%)
Closing price 02/21/2025 03:59 PM Eastern
Extended Trading
$1.14 +0.05 (+4.59%)
As of 02/21/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Opus Genetics SEC Filings

DateFilerForm TypeView
02/07/2025
10:41 AM
Opus Genetics, Inc. (Subject)
Opus Genetics, Inc. (Subject)
Opus Genetics (Subject)
Sooch Mina (Filed by)
Form DFAN14A
02/06/2025
3:37 PM
Opus Genetics, Inc. (Issuer)
Opus Genetics, Inc. (Issuer)
Opus Genetics (Issuer)
Zaremba Rabourn Amy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
02/06/2025
3:35 PM
Hoffmann Bernhard (Reporting)
Opus Genetics, Inc. (Issuer)
Opus Genetics, Inc. (Issuer)
Opus Genetics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/24/2025
3:34 PM
Opus Genetics, Inc. (Filer)
Opus Genetics, Inc. (Filer)
Opus Genetics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/23/2025
4:20 PM
Opus Genetics, Inc. (Filer)
Opus Genetics, Inc. (Filer)
Opus Genetics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/14/2025
8:10 AM
Opus Genetics, Inc. (Filer)
Opus Genetics, Inc. (Filer)
Opus Genetics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2025
4:29 PM
Opus Genetics, Inc. (Filer)
Opus Genetics, Inc. (Filer)
Opus Genetics (Filer)
Form 424B5
01/07/2025
4:10 PM
Opus Genetics, Inc. (Filer)
Opus Genetics, Inc. (Filer)
Opus Genetics (Filer)
Form 8-K/A
01/06/2025
3:42 PM
Bennett Jean (Reporting)
Opus Genetics, Inc. (Issuer)
Opus Genetics, Inc. (Issuer)
Opus Genetics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/06/2025
3:43 PM
MANUSO JAMES S J (Reporting)
Opus Genetics, Inc. (Issuer)
Opus Genetics, Inc. (Issuer)
Opus Genetics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2024
3:26 PM
Magrath George (Reporting)
Opus Genetics, Inc. (Issuer)
Opus Genetics, Inc. (Issuer)
Opus Genetics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/23/2024
4:50 PM
Magrath George (Reporting)
Opus Genetics, Inc. (Issuer)
Opus Genetics, Inc. (Issuer)
Opus Genetics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/25/2024
3:18 PM
Opus Genetics, Inc. (Issuer)
Opus Genetics, Inc. (Issuer)
Opus Genetics (Issuer)
YERXA BENJAMIN R (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
11/07/2024
5:08 AM
Opus Genetics, Inc. (Filer)
Opus Genetics, Inc. (Filer)
Opus Genetics (Filer)
Form D
Notice of Exempt Offering of Securities 
11/05/2024
3:13 PM
Magrath George (Reporting)
Opus Genetics, Inc. (Issuer)
Opus Genetics, Inc. (Issuer)
Opus Genetics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
11/04/2024
4:07 PM
Opus Genetics, Inc. (Filer)
Opus Genetics, Inc. (Filer)
Opus Genetics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
10/29/2024
4:26 PM
Foundation Fighting Blindness Retinal Degeneration Fund (Filed by)
Opus Genetics, Inc. (Subject)
Opus Genetics, Inc. (Subject)
Opus Genetics (Subject)
Form SC 13D
10/29/2024
4:10 PM
Foundation Fighting Blindness Retinal Degeneration Fund (Reporting)
Foundation Fighting Blindness, Inc. (Reporting)
Opus Genetics, Inc. (Issuer)
Opus Genetics, Inc. (Issuer)
Opus Genetics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
10/24/2024
4:54 PM
Opus Genetics, Inc. (Issuer)
Opus Genetics, Inc. (Issuer)
Opus Genetics (Issuer)
YERXA BENJAMIN R (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
10/24/2024
4:56 PM
Bennett Jean (Reporting)
Opus Genetics, Inc. (Issuer)
Opus Genetics, Inc. (Issuer)
Opus Genetics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2024
4:59 PM
Graves Adrienne L (Reporting)
Opus Genetics, Inc. (Issuer)
Opus Genetics, Inc. (Issuer)
Opus Genetics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
10/24/2024
4:49 PM
Bennett Jean (Reporting)
Opus Genetics, Inc. (Issuer)
Opus Genetics, Inc. (Issuer)
Opus Genetics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
10/24/2024
4:52 PM
Graves Adrienne L (Reporting)
Opus Genetics, Inc. (Issuer)
Opus Genetics, Inc. (Issuer)
Opus Genetics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
10/22/2024
4:09 PM
Ocuphire Pharma, Inc. (Filer)
Ocuphire Pharma, Inc. (Filer)
Opus Genetics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/13/2024
7:14 AM
Ocuphire Pharma, Inc. (Filer)
Ocuphire Pharma, Inc. (Filer)
Opus Genetics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/13/2024
4:30 PM
Ocuphire Pharma, Inc. (Issuer)
Ocuphire Pharma, Inc. (Issuer)
Opus Genetics (Issuer)
Pepose Jay (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2024
4:31 PM
Ocuphire Pharma, Inc. (Issuer)
Ocuphire Pharma, Inc. (Issuer)
Opus Genetics (Issuer)
Rodgers Richard J (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2024
4:23 PM
Ainsworth Sean (Reporting)
Ocuphire Pharma, Inc. (Issuer)
Ocuphire Pharma, Inc. (Issuer)
Opus Genetics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2024
4:25 PM
Benton Susan (Reporting)
Ocuphire Pharma, Inc. (Issuer)
Ocuphire Pharma, Inc. (Issuer)
Opus Genetics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2024
4:27 PM
Gallagher Cam (Reporting)
Ocuphire Pharma, Inc. (Issuer)
Ocuphire Pharma, Inc. (Issuer)
Opus Genetics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2024
4:28 PM
MANUSO JAMES S J (Reporting)
Ocuphire Pharma, Inc. (Issuer)
Ocuphire Pharma, Inc. (Issuer)
Opus Genetics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2024
3:06 PM
Ocuphire Pharma, Inc. (Filer)
Ocuphire Pharma, Inc. (Filer)
Opus Genetics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/24/2024
3:07 PM
Jayagopal Ashwath (Reporting)
Ocuphire Pharma, Inc. (Issuer)
Ocuphire Pharma, Inc. (Issuer)
Opus Genetics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2024
3:18 PM
Magrath George (Reporting)
Ocuphire Pharma, Inc. (Issuer)
Ocuphire Pharma, Inc. (Issuer)
Opus Genetics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/10/2024
3:35 PM
Ocuphire Pharma, Inc. (Filer)
Ocuphire Pharma, Inc. (Filer)
Opus Genetics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
05/10/2024
7:12 AM
Ocuphire Pharma, Inc. (Filer)
Ocuphire Pharma, Inc. (Filer)
Opus Genetics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/29/2024
3:43 PM
Ocuphire Pharma, Inc. (Filer)
Ocuphire Pharma, Inc. (Filer)
Opus Genetics (Filer)
Form DEFA14A
04/29/2024
3:45 PM
Ocuphire Pharma, Inc. (Filer)
Ocuphire Pharma, Inc. (Filer)
Opus Genetics (Filer)
Form ARS
04/19/2024
4:28 PM
Ocuphire Pharma, Inc. (Filer)
Ocuphire Pharma, Inc. (Filer)
Opus Genetics (Filer)
Form PRE 14A
04/17/2024
3:23 PM
Ocuphire Pharma, Inc. (Filer)
Ocuphire Pharma, Inc. (Filer)
Opus Genetics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/20/2024
3:18 PM
Magrath George (Reporting)
Ocuphire Pharma, Inc. (Issuer)
Ocuphire Pharma, Inc. (Issuer)
Opus Genetics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry." (Ad)

If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.

03/08/2024
4:20 PM
Ocuphire Pharma, Inc. (Filer)
Ocuphire Pharma, Inc. (Filer)
Opus Genetics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
03/08/2024
7:21 AM
Ocuphire Pharma, Inc. (Filer)
Ocuphire Pharma, Inc. (Filer)
Opus Genetics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:IRD) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners